Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 2156 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Degludec insulin: A novel basal insulin

Kalra Sanjay, Unnikrishnan Ambika Gopalakrishnan, Baruah Manash, Kalra Bharti

Year : 2011| Volume: 15| Issue : 5 | Page no: 12-16

   This article has been cited by
 
1 Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
Yuji Kawaguchi,Jun Sawa,Chie Hamai,Yasuro Kumeda
Diabetes Therapy. 2019; 10(4): 1535
[Pubmed]  [Google Scholar] [DOI]
2 Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
Yuji Kawaguchi,Jun Sawa,Chie Hamai,Yuri Nishimura,Yasuro Kumeda
Journal of Diabetes Investigation. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 RSSDI consensus recommendations on insulin therapy in the management of diabetes
R. Chawla,B. M. Makkar,S. Aggarwal,S. Bajaj,A. K. Das,S. Ghosh,A. Gupta,S. Gupta,S. Jaggi,J. Jana,J. Keswadev,S. Kalra,P. Keswani,V. Kumar,A. Maheshwari,A. Moses,C. L. Nawal,J. Panda,V. Panikar,G. D. Ramchandani,P. V. Rao,B. Saboo,R. Sahay,K. R. Setty,V. Viswanathan,SR Aravind,S Banarjee,A Bhansali,HB Chandalia,S Das,OP Gupta,S Joshi,A Kumar,KM Kumar,SV Madhu,A Mittal,V Mohan,C Munichhoodappa,A Ramachandran,BK Sahay,J Sai,V Seshiah,AH Zargar
International Journal of Diabetes in Developing Countries. 2019; 39(S2): 43
[Pubmed]  [Google Scholar] [DOI]
4 Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles
Yuji Kawaguchi,Jun Sawa,Noriko Sakuma,Yasuro Kumeda
Journal of Diabetes Investigation. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Antihyperglycemic Medications
Karen Beer
Physician Assistant Clinics. 2017; 2(1): 25
[Pubmed]  [Google Scholar] [DOI]
6 Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
Sanjay Kalra,ZafarA Latif,Abdurrahman Comlekci,GuillermoGonzalez Galvez,Rached Malik,MdFaruque Pathan,Ajay Kumar
Indian Journal of Endocrinology and Metabolism. 2016; 20(4): 542
[Pubmed]  [Google Scholar] [DOI]
7 Injectable Coformulations in Diabetology
Sanjay Kalra,Yashdeep Gupta
Diabetes Therapy. 2015;
[Pubmed]  [Google Scholar] [DOI]
8 Structural and Functional Study of the GlnB22-Insulin Mutant Responsible for Maturity-Onset Diabetes of the Young
Kvetoslava Krížková,Václav Veverka,Lenka Maletínská,Rozálie Hexnerová,Andrzej M. Brzozowski,Jirí Jirácek,Lenka Žáková,Vladimir N. Uversky
PLoS ONE. 2014; 9(11): e112883
[Pubmed]  [Google Scholar] [DOI]
9 Insulin and value-added therapy
Sanjay Kalra,ManashP Baruah,Yashdeep Gupta
Journal of Social Health and Diabetes. 2014; 2(2): 59
[Pubmed]  [Google Scholar] [DOI]
10 Improving adherence to insulin: Hope with degludec
Sanjay Kalra,AG Unnikrishnan,AK Das
Journal of Social Health and Diabetes. 2014; 2(1): 1
[Pubmed]  [Google Scholar] [DOI]
11 Nueva insulina basal de acción ultralenta: insulina degludec
Rafael Simó
Avances en Diabetología. 2013; 29(1): 4
[Pubmed]  [Google Scholar] [DOI]
12 The Future of Basal Insulin
Viral N. Shah,Emily G. Moser,Aaron Blau,Megha Dhingra,Satish K. Garg
Diabetes Technology & Therapeutics. 2013; 15(9): 727
[Pubmed]  [Google Scholar] [DOI]
13 Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
Sanjay Kalra
Diabetes Therapy. 2013;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article